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Edited by Judit Ova´diAbstract The H-bonded complex of ATP with Arg 34 of Zn2+
ﬁnger I of poly-ADP-ribose polymerase-1 (PARP-1) determines
trans-oligo-ADP-ribosylation from NAD+ to proteins other than
PARP-1. This mechanism was tested in lysolecithin fractions of
non-malignant and cancer cells separately and after their recom-
bination. Cellular PARP-1 activity was recovered when the cen-
trifugal sediment was recombined with the supernatant fraction
containing cellular ADP-ribose oligomer acceptor proteins.
Combination of the matrix fraction (Mx) of cancer cells (lacking
OXPHOS) with its supernatant had the same PARP-1 activity
as the Mx alone.
The supernatant of non-malignant cells was replaced by glyco-
lytic enzymes as ADP-ribose acceptor. The hexokinase activity
of the supernatant increased when OXPHOS of intact cells
was uncoupled by carbonyl cyanide 4-(triﬂuoro methoxy) phen-
ylhydrazone. trans-ADP-ribosylation was demonstrated by poly-
acrylamide gel electrophoresis.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Macromolecular associative control1. Introduction
The enzymatic process catalyzed by poly-ADP-ribose poly-
merase-1 (PARP-1) (E.C. 2.4.2.30) commences with the trans-
fer of one ADP-ribose moiety of the donor NAD+ to
ultimately a glutamyl residue of PARP-1 to form a hydroxyl-
amine hydrolyzable ester bond that distinguishes it from
mono-ADP-ribose transferases [1]. The penultimate chemical
species preceding the glutamyl ester is an unstable imidazolyl
ADP-ribose [2] positioned on a speciﬁc histidine residue of
PARP-1, which forms a ‘‘head to tail’’ dimer required for enzy-Abbreviations: PARP-1, poly-ADP-ribose polymerase-1; LL, lysolec-
ithin; Mx, matrix fraction; Su, metabolic fraction; AK, adenylate
kinase; HK, hexokinase; FCCP, carbonyl cyanide 4-(triﬂuoro meth-
oxy) phenylhydrazone
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doi:10.1016/j.febslet.2008.06.052matic activity (cf. [3,4]). Once the glutamyl ester is synthesized
on PARP-1 it is either elongated to oligo-ADP-ribose on
PARP-1 (auto-ADP-ribosylation) or the ADP-ribose moiety
is transferred to a glutamyl residue of another protein: trans-
ADP-ribosylation. These two reactions were thought to be
random, hence poly-ADP-ribosylation was conventionally de-
ﬁned as a general protein modifying process [5]. Since poly-
ADP-ribose is already formed from NAD+ at pH 8.0 in the
presence of high concentrations of non-physiological catalytic
peptide of PARP-1 alone [6], it can be concluded that ‘‘coenzy-
mic’’ DNA is a catalyst of the facile polymerization of ADP-
ribose. There are several DNA structures that bind to
PARP-1 (e.g. cruciform, bent and DNA sequences) and can
act as co-enzymatic DNAs of PARP-1 (cf. [7]); thus our choice
of dA18/dT18 is based on the relative ease of its preparation
(Ref. [1] in [8]) and permitting quantitative enzyme kinetics
in contradistinction to DNAase-digested DNA as co-enzyme.
Contrary to the notion that trans-ADP-ribosylation is a ran-
dom process [5], we present evidence here that the previously
deﬁned ATP complex with Arg 34 of Zn2+ ﬁnger I of PARP-
1 [8] directs trans-ADP-ribosylation to metabolically impor-
tant glycolytic enzymes of the cell nucleus that generate glyco-
lytic ATP speciﬁcally required for DNA synthesis, a reaction
particularly important in the cancerous cellular phenotype.
The second, highly pH-sensitive component reaction of
poly-ADP-ribosylation is related to the intrinsic NAD+-glyco-
hydrolyse activity of PARP-1, generating free ADP-ribose.
Due to the aldehydic nature of ADP-ribose, it readily forms
Schiﬀ bases [9] with the amino group of lysine side chains
and is the major macromolecular product of PARP-1-cata-
lyzed reactions at pH 8.0. The Schiﬀ bases are also initiator
sites of poly-ADP-ribose formation and contribute to its
branched structure [5]. However, Schiﬀ base formation at pH
7.2 and 100 lM NAD+ as ADP-ribose donor is only 20–30%
of the sum of PARP-1 catalyzed products as determined by
speciﬁc trapping of ADP-ribose, a subject to be detailed
elsewhere.
In the present paper, we describe an extension of the lysolec-
ithin (LL) technique [8] and show a rapid separation of cellular
components into a soluble and readily extractable fraction
called metabolic fraction (Su), and the nuclear-mitochondrial
matrix fraction (Mx) which retains cellular structures. Quanti-
tative enzymatic analyses with these fractions and particularly
their reconstitution identiﬁes trans-ADP-ribosylation, and we
demonstrate the pivotal role of PARP-1 in connectingblished by Elsevier B.V. All rights reserved.
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mRNA synthesis [8] and DNA synthesis.PA
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Fig. 1. Recombination of LL fractions. Cells were permeabilized with
LL as described [10], and PARP-1 activity was tested in the following
combinations: total permeabilized cell suspension (1, 5, 8), re-
suspended sediment ‘‘Matrix’’ (Mx) (2, 6, 9), supernatant (Su), and
their combination in each triplicate.2. Materials and methods
2.1. The LL–Mx method
Detached cells or centrifugal cells from suspension cultures (3–
5) · 106 cells suspended in 400 ll solution A (cf. [10]) containing
0.2 mg LL/ml were kept in an ice bath for 2 min and resedimented at
0 C. The sediment (Mx) and the supernatant (Su) were assayed for
PARP-1 activity [10] as described in Section 3. Su contains 30–40%
of cellular protein. Hexokinase activity was assayed at 25 C in Su
(equivalent to 1.1 · 106 cells) by direct spectrophotometric rate mea-
surement of NADPH formation in a test system containing Tris–
Mg2+ buﬀer (50 mM Tris, pH 8.0, 13 mM MgCl2), glucose
(100 mM), ATP (0.55 mM), NADP (0.22 mM), glucose-6-phosphate
dehydrogenase Type XV (Sigma 1.2 units) using the Shimadzu UV-
1650PC system. The cell culture conditions, analytical methods and
exposure to carbonyl cyanide 4-(triﬂuoro methoxy) phenylhydrazone
(FCCP) were the same as previously reported [8].
We extended the list of cell cultures from four (cf. [8] to additional
cell types: HL-60 (Promyelocytic leukemia), MEF (mouse embryonic
ﬁbroblasts which were freshly prepared and tested after two passages),
E-ras 20 cells [11], and PARP-1/MEF cells to illustrate the validity
of the role of PARP-1. PARP-1/ mice were a gift received from Er-
win Wagner, Inst. Mol. Pathol., Univ. Vienna. MEF cells and MEF
PARP-1/ cells were cultured in DMEM medium + 10% FBS until
subconﬂuency, then treated with LL as reported [10]. HL-60 cells were
cultured in RPM1 1640 medium. Assays for ATP content and ATP
deligation test were performed as reported [8], and all cell types gave
the same ATP content (2.8–3.0 mM) and exhibited ATP homeostasis
[8]. HL-60 and E-ras cells had no detectable OXPHOS activity (not
shown). Gel electrophoretic separation of PARP-1 hexokinase (HK)
and histone H1 complexes of PARP-1 were carried out by methods re-
ported earlier [12,13].3. Results and discussion
3.1. Reconstitution of Mx and Su with respect to PARP-1
activity
The LL–Mx technique (see Section 2) permits rapid and
quantitative separation of a soluble Su fraction from struc-
ture-associated PARP-1 that also contains all cellular mito-
chondria [8]. Since the quantitation of PARP-1 in LL-
permeabilized whole cells showed high PARP-1 in contrast to
the sedimented Mx fraction, it was apparent that the Su frac-
tion served as source of ADP-ribose acceptor proteins, ADP-ri-
bose being generated in the Mx fraction [8]. It is this Mx
fraction that shows de-inhibition of PARP-1 activity by ATP
when intracellular OXPHOS is blocked and the transfer of
ATP via the ‘‘adenylate kinase (AK) wire’’ is inhibited by
FCCP [8]. This prediction was veriﬁed experimentally as shown
in Fig. 1. In this ﬁgure, bars 1–4 represent results with non-
malignant CV-1 cells, each bar being the mean value of tripli-
cates (n = 12, S.D. ± 8–12% of the mean). A markedly diﬀerent
reconstitution pattern is found in triplicates of malignant cells
(n = 12, S.D. = 8–11% of the mean, bars 5–9, E-ras 20 and
HL-60 cells). Although in malignant cells the Mx fraction also
physically separates from Su with centrifugation, PARP-1
activity is identical in both Mx and Su + Mx because the lack
of OXPHOS in tumor cells eliminates the strongly inhibitory
eﬀect of AK–ATP in Mx [8]. It should be noted that the ATP
concentration in the AK–ATP complex is maximally 35 lM,
which is the Km for ATP [15], and is therefore about 100 times
smaller that the Ki of externally added free ATP (3 mM) [8].The concurrence of the strong inhibition of auto-oligo-ADP-
ribosylation in non-malignant cells by the AK–ATP complex
with the active trans-ADP-ribosylation of proteins added to
Mx indicates that AK–ATP is required in trans-oligo-ADP-
riboylation.
The role of acceptor proteins for trans-ADP-ribosylation in
CV-1 cells was determined by substituting glycolytic enzymes
for Su, as illustrated in Fig. 2. Various concentrations of lac-
tate dehydrogenase, HK and Enolase fully replaced the Su
fractions, indicating varying degrees of oligo-ADP-ribosly-
ation of these enzymes.
Similar to results given in Fig. 1, ﬁve bars in Fig. 2 are the
average of triplicate PARP-1 assays (n = 15, S.D. ± 11% of
mean) in CV-1 cells. It is known that certain glycolytic
enzymes associate with ssDNA in the nucleus and severely
modify DNA activity [20]. Oligo-ADP-ribosylation of these
glycolytic enzymes most probably can also modify their eﬀect
on DNA, just as was observed with HK.
Since HK is the initiator enzyme of glycolysis from glucose,
this enzyme was assayed in the Su fraction of CV-1 cells. Anal-
ogous to deligation studies with ATP [8], we determined the
consequences of deligation of ATP by FCCP on the HK activ-
ity of Su of CV-1 cells, anticipating subsequent de-ADP-ribo-
sylation (by poly-ADPR glycohydrolase) and de-inhibition of
HK, provided the t1/2 of the oligo-ADP-ribose is within 2 h.
This prediction was veriﬁed as seen in Fig. 3, which is a kinetic
tracing of HK activity. Preincubation of CV-1 cells with FCCP
for 2 h (cf. [8]) indeed increased HK activity, which was max-
imal in Su of malignant cells possessing no OXPHOS, and
thereby lacking the inhibition of HK by trans-oligo-ADP-ribo-
sylation. The time course of HK rates, as followed by kinetic
tracing, was calculated per 1.1 · 106 cells, which does not take
into account diﬀerences in cell volume. We corrected for diﬀer-
ences in cell volume and the results are given in Table 1, show-
ing that deligation with FCCP raises HK activity of CV-1 cells
to nearly 1/2 of the maximal rates obtained in tumor cells
where OXPHOS is absent. We present the de-inhibition of
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Fig. 2. Replacement of Su by glycolytic enzymes in CV-1 cells.
Symbols are the same as in legend of Fig. 1. Glycolytic enzymes were
obtained from Sigma: LDH = cat. #L3888, HK = cat. #H5000,
Enolase = cat. #E6126.
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Fig. 3. Time course of HK activity in Su fractions. The composition of
the test system is given in Section 2, and the assay was performed in
triplicates (S.D. ± 2%) in 1 ml quartz cuvettes containing Su equivalent
to 1.1 · 106 cells.
Table 1
Calculated HK rates
Cell type Reaction rate
(nmol/min/ll)
Cell volume
(ll/106 cells)
CV-1 0.106 3.7
CV-1 + FCCP 0.245 3.7
E-ras 20 0.470 2.3
HL-60 0.450 1.1
n = 3, S.D. ± 2% n = 3, S.D. ± 12%
Reaction rates were read from Fig. 3 and cell volumes were measured
in Kimax (No. 45225) graduated centrifuge tubes.
Fig. 4. Gel electrophoresis of proteins associated with PARP-1.
PARP-1 activity was assayed [10] in presence of 75 lM biotinylated
NAD+ (Trevigen) as ADP-ribose donor and cofactors for 10 min. In
recombination tests, Su (equivalent to 5 · 104 cells) was replaced by
histone H1 or HK, both puriﬁed to homogeneity (0.5 lg each).
Reactions were quenched with an equal volume of Laemmli buﬀer, and
gel electrophoresis and transblot were performed as reported [13].
Oligo-ADP-ribosylated proteins were tagged with streptavidine–HPO
(1 lg/ml for 2 h) and visualized by FCL [13]. Cloned human PARP-1
[16] served as a molecular mass marker. For explanation of Lanes
1–12, see Section 3.
E. Kun et al. / FEBS Letters 582 (2008) 2709–2713 2711HK by uncoupling of OXPHOS here because it more closely
reﬂects intracellular conditions and illustrates the kinetics of
enzyme inhibitory action of trans-oligo-ADP-ribosylation. It
is of importance to note that varying degrees of inhibition of
enzymatic components in a sequential pathway predict overall
synergistic inhibitory kinetics [14]; thus the cellular eﬀect of
varying degrees of inhibition of glycolytic enzymes is expected
to be far greater than measured with one enzymatic
component.In Fig. 4, the donor of ADP-ribose was biotinylated NAD+,
visualized by the streptavidine method (see legend to Fig. 4)
which is a transblot of an SDS gel of LL-treated MEF cells.
Lane 1 shows the background in the absence of the NAD+
analog, while Lane 2 demonstrates the eﬀect of dA/
dT + spermine on protein labeling. Lane 3 demonstrates the
association of oligo-ADP-ribosylated proteins present in Su
with PARP-1 in presence of cofactors, Lane 4 that of HK,
and Lane 5 that of histone H1 (both with cofactors). PARP-
1 activity of HL-60 cells is shown in Lane 7 in presence of
dA/dT + spermine and in Lane 8 without these cofactors. Here
proteins failed to accumulate at the level of PARP-1 in HL-60
cells, demonstrating the absence of trans-ADP-ribosylation in
these cancer cells, reminiscent of the pattern shown in Fig. 1.
Lane 9 demonstrates that PARP-1/ cells show no reaction.
When cloned PARP-1 (0.2 lg) was re-added to LL-treated
PARP-1/ cells, activity re-appeared (Lane 10), demonstrat-
ing the absolute dependence of observed reactions on PARP-
1. Lanes 11 and 12 demonstrate the eﬀect of dA/dT + spermine
and of Su added to PARP-1/ cells, illustrating that trans-
ADP-ribosylation was catalyzed by PARP-1 added externally
to these cells.
Since results with protein gels are at best semiquantitative,
we repeated them with 3H-NAD+ and calculated the quantity
of oligo-ADP-ribosylated proteins as in Figs. 1 and 2.
Although the PARP-1 content of MEF cells was about 1/2 that
of CV-1 cells, identical patterns of oligo-ADP-ribosylated pro-
teins were obtained in MEF and CV-1 cells (results not
shown). It is evident that PARP-1 does not separate from its
trans-ADP-ribosylation counterproteins because the PARP-1
oligo-ADP-ribose complex is a structure held together by
2712 E. Kun et al. / FEBS Letters 582 (2008) 2709–2713covalent bonds: glutamyl esters and lysine Schiﬀ bases. Ab-
sence of PARP-1 as in PARP-1/ cells abrogates these phe-
nomena, pinpointing the critical function of PARP-1. We
conclude from results shown in Fig. 4 that NAD+ plays a spe-
ciﬁc co-enzymatic role in macromolecular associations besides
being the redox catalyst to dehydrogenases.
The most economic interpretation of trans-oligo-ADP-ribo-
sylation is based on enzyme kinetic results [16]. As we show,
ATP competes with coenzymic DNA, a competitive inhibition
that is much greater with the AK–ATP complex [8] than with
added ATP. Accordingly, the initial PARP-1–ADP-ribose
complex cannot elongate on the same site. The large Hill coef-
ﬁcient, measured following addition of spermine to isolated
PARP-1 [16] is an indication of signiﬁcant allosteric modiﬁca-
tion of PARP-1, favoring the transfer of imidazolyl ADP-ri-
bose from histidine (probably His62 or 66 which are in the
vicinity of the active center of the dimer [3]) to a glutamyl res-
idue [2] of the acceptor protein. A more rigorous model de-
pends on X-ray crystallographic protein structural analysis, a
work in progress.
Inhibition or de-inhibition of nuclear glycolysis by the
‘‘ATP-wire’’-mediated mechanism [8] has profound eﬀects on
DNA synthesis as predictable from a special nuclear role of
glycolytic enzymes [17,20]. Oligo-ADP-ribosylation of a pro-
tein deﬁnes its nuclear exposure to PARP-1. Hexokinase is
measurable in the Su fraction (Fig. 3) and its inhibition pro-
portionally inhibits glycolytic ATP synthesis. We have shown
experimentally that DNA synthesis depends on glycolytic
ATP synthesis, and further that DNA synthesis requires added
DNAase I-digested DNA as a source of DNA templates for
maximal activity only in cancer cells [10]; hence DNA synthesis
in these cells is abnormal. Sustained uncoupling as it exists in
cancer cells therefore promotes this abnormally increased
DNA synthesis. Besides failing to serve as eﬃcient templates
for DNA synthesis [10] intracellular coenzymic function of
DNA on PARP-1 is also missing (results not shown), and as
shown here there is no trans-ADP-ribosylation in malignant
cells. The elucidation of the nature of these DNA defects in
cancer cells is part of ongoing work. We have reported that
dexamethasone-stimulated DNA synthesis in a cell line con-
taining an EJ-ras gene construct (14C cells) is selectively inhib-
ited by blocking the activity of PARP-1 [18], demonstrating a
mechanistic relationship between PARP-1 activity and DNA
synthesis in malignant cells, as reported here.
We have also reported that in regenerating rat liver, similar
to the situation in 14C cells, PARP-1 is associated in the nucle-
ar ‘‘M’’ band with DNA polymerase b [21] and this relocation
of PARP-1 from DNA polymerase a to b may explain its di-
rect eﬀect on growth-related DNA synthesis.
A large number of reports has identiﬁed important cellular
proteins such as tumor suppressors and transcriptional factors
[19] as targets of trans-oligo-ADP-ribosylation. These enzy-
matic assays were performed at alkaline pH with high
NAD+ as ADP-ribose donor; therefore it is uncertain whether
these experiments represent chemical artifacts or real enzy-
matic reactions. Furthermore, the demonstrated involvement
of OXPHOS in poly-ADP-ribosylation reactions [8] necessi-
tates reinvestigation of trans-ADP-ribosylating systems target-
ing regulatory proteins.
Prior to our previous report [8] and the present paper,
PARP-1 activity was generally thought to be restricted to reg-
ulation of cellular pathways by covalent modiﬁcation of criti-cal proteins. In contrast, we show here that PARP-1 actually
participates in major cellular events such as mRNA [8] and
DNA synthesis, the latter by direct modiﬁcation of glycolytic
enzymes providing the ATP for DNA synthesis. Furthermore,
we conclude that OXPHOS itself plays a major cellular regula-
tory function [8], and is not just a cellular generator of ATP.
These results orient PARP-1 research to new directions and
call for re-interpretation of presently held views. A major ﬁeld
of cell biology is cell death [22] where PARP-1 has been impli-
cated [23,24]. Mechanisms of cell death now can be expanded
to include derangement of ﬁne tuning of mRNA and DNA
syntheses. In addition, the unique tumor cell killings by
iodo-nitro prodrugs now ﬁnds explanation in uncoupling of
OXPHOS in tumor cells, which leads to incomplete reduction
of a nitro group to the cytocidal nitroso species [25], a
mechanism operative also in HIV retrovirus synthesizing cells
[26].
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